Methodology: Regenerative Medicine Deals

For deal-making trends, deals are grouped into three main categories: gene therapy, cell therapy and tissue regeneration. There may be overlap among the categories in terms of deals included in each if they cross over more than one of those categories. The sources for these data are Informa's Medtrack and Strategic Transactions. The regenerative medicine industries covered from Medtrack include biomaterials and tissue regeneration (which were included in the tissue regeneration category), in vivo and ex vivo gene therapy (in the gene therapy category) and stem cell therapy (in the cell therapy category). Within Medtrack's partnership classification are funding/grant announcements, as well as some deals focused on the veterinary market. The regenerative medicine industries covered from Strategic Transactions include "gene therapy, cell therapy" and biomaterials. The deals labeled "gene therapy, cell therapy" were individually reviewed and placed into one or more of the three main categories. The biomaterials deals were included in the tissue regeneration category. Keyword searching of deal summaries was also used in Strategic Transactions to identify regenerative medicine deals. Gene editing deals are included in the gene therapy category.